檢索結果 - Catherine E. Chaillan Huntington

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction

    Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction 由 Elizabeth England, D. Gareth Rees, Ian C. Scott, Sara Carmen, Denice T. Y. Chan, Catherine E. Chaillan Huntington, Kirsty F. Houslay, Teodor Erngren, Mark Penney, Jayesh B. Majithiya, Laura Rapley, Dorothy A. Sims, Claire Hollins, Elizabeth C. Hinchy, Martin Strain, Benjamin Kemp, Dominic J. Corkill, Richard May, Katherine A. Vousden, Robin Butler, Tomas Mustelin, Tristan J. Vaughan, David C. Lowe, Caroline Colley, E. Suzanne Cohen

    出版 2023
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation

    Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation 由 E. Suzanne Cohen, Ian C. Scott, Jayesh B. Majithiya, Laura Rapley, Benjamin Kemp, Elizabeth England, D. Gareth Rees, Catherine L. Overed‐Sayer, Joanne Woods, Nicholas J. Bond, Christel Séguy Veyssier, Kevin J. Embrey, Dorothy A. Sims, Michael Snaith, Katherine A. Vousden, Martin Strain, Denice T. Y. Chan, Sara Carmen, Catherine E. Chaillan Huntington, Liz Flavell, Jianqing Xu, Bojana Popovic, Christopher E. Brightling, Tristan J. Vaughan, Robin Butler, David C. Lowe, Daniel R. Higazi, Dominic J. Corkill, Richard May, Matthew A. Sleeman, Tomas Mustelin

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: